HRT Side Effects and Benefits: An Honest Balance Sheet Based on the Latest Evidence

The waiting-room conversation has shifted. A decade ago, a woman asking about menopause treatment often opened with an apology, as if the question itself were reckless. Now she arrives with a screenshot. In November 2025 the US drug regulator announced it would remove the boxed warning that had sat on menopausal hormone products since the early 2000s, and the news traveled through group chats faster than most clinical guidance ever does. As of early 2026, searches for HRT side effects and HRT benefits are climbing together, which tells you something: people want the whole ledger, not a verdict.

That ledger is more interesting than either camp admits. Some risks are real and measurable. Some benefits are among the best-proven in women’s health. And a surprising amount of what circulates online comes from a single 2002 headline about women whose average age was 63.

So here is the balance sheet, drawn from the trials and the long follow-ups, with the strength of each claim stated plainly.

What changed recently, and why HRT side effects are back in the headlines

Three dates explain the current moment. The first is July 2002, when the Women’s Health Initiative (WHI), a large randomized trial funded by the US National Institutes of Health, stopped its combined estrogen-plus-progestogen arm early after finding more breast cancers, strokes and blood clots than expected. Prescriptions fell sharply within two years, and the boxed warning that followed shaped how a generation of clinicians talked about hormone therapy.

The second date is September 2017, when an 18-year follow-up of 27,347 WHI participants was published in JAMA. Women who had been assigned to hormone therapy for a median of five to seven years were no more likely to have died from any cause, from cardiovascular disease or from cancer than women assigned to placebo. That finding did not erase the original risks, but it reframed them as smaller and more time-limited than the 2002 coverage implied.

The third date is November 2025, when US regulators announced plans to remove the boxed warning about cardiovascular disease, breast cancer and probable dementia from menopausal hormone products, while keeping product-specific warnings in the detailed labeling. Patient guidance from the NHS, Mayo Clinic and Cleveland Clinic had already moved toward individual assessment based on age, time since menopause and personal history rather than a blanket caution.

None of these events changed the biology. What changed is how the same data are weighed, and for whom. A 52-year-old with disruptive night sweats and no clotting history sits in a very different part of the ledger than the typical WHI participant, and the updated guidance says so out loud.

HRT is not one thing: why type, route and timing decide the side effects

Much confusion comes from treating HRT as a single product. Hormone replacement therapy, also called menopausal hormone therapy, is a family of treatments, and the side effect profile shifts with each choice.

Systemic HRT travels through the bloodstream and treats whole-body symptoms. Local HRT means low-level vaginal estrogen that works mainly on nearby tissue, with very little absorbed; its risk profile is close to that of no systemic treatment, which is why it is discussed separately throughout this piece.

Estrogen-only therapy is typically used by women who have had a hysterectomy. Combined therapy adds a progestogen, the umbrella term for natural progesterone and synthetic progestins, to protect the endometrium, the lining of the womb, which thickens under unopposed estrogen and can become cancerous. Most of the breast cancer signal in trials belongs to the combined arm, not the estrogen-only arm.

Route matters as much as content. Oral estrogen passes through the liver first, where it nudges clotting proteins upward. Transdermal estrogen, delivered by patch, gel or spray through the skin, largely bypasses that first pass. The randomized evidence for clot risk comes mostly from oral products; the reassurance about transdermal products comes mostly from observational studies, which is an important distinction we return to later.

Finally there is timing. Starting before 60 or within 10 years of the final period lands in the zone where benefits most often outweigh risks in the data. Starting later, particularly after 65, moves several risks upward. The phrase “body-identical” refers to regulated estradiol and micronized progesterone that match the molecules the ovaries make; “compounded bioidentical” products are custom-mixed, unapproved and untested in trials, and are not for self-use.

HRT benefits: what the strongest evidence supports

Start with the benefit that brings most people to the clinic. Hot flashes and night sweats, grouped as vasomotor symptoms because they involve sudden widening of skin blood vessels, respond to systemic estrogen better than to any other treatment studied. Pooled randomized trials show frequency falling by roughly three-quarters compared with placebo, and severity dropping alongside. This is high-certainty evidence, replicated across decades.

Bone comes next. Estrogen slows the bone-breakdown that accelerates after menopause. In the WHI, women on combined therapy had about five fewer hip fractures per 10,000 woman-years than women on placebo, with reductions in spine and total fractures too. Systemic HRT is approved for preventing osteoporosis in women at elevated risk, though the protection fades after stopping.

Genitourinary syndrome of menopause, the cluster of vaginal dryness, pain with sex, urgency and recurrent urinary infections caused by thinning, estrogen-starved tissue, improves with local vaginal estrogen in randomized trials, and systemic therapy helps as well.

Some benefits are real but indirect. Sleep often improves because night sweats stop; mood often steadies for the same reason, with modest trial evidence of a direct effect on low mood around the menopause transition for some women. Joint aches, brain fog and skin changes show up constantly in patient reports, yet trial evidence for those outcomes is thin, so clinicians describe them as possible rather than expected.

One finding surprised the WHI investigators: about six fewer colorectal cancers per 10,000 woman-years in the combined arm. The mechanism remains unclear, and HRT is not prescribed for that purpose. Heart disease deserves its own section, because the answer depends almost entirely on age.

HRT side effects in the first months: what settles and what does not

The body treats the first weeks of HRT the way it treats a new altitude: with adjustment symptoms that mostly pass. The NHS lists breast tenderness or swelling, nausea, bloating, headaches, leg cramps, indigestion and mood changes as common early effects, and notes they usually ease within about three months as hormone levels stabilize.

Breast tenderness is the most frequent complaint and is driven by estrogen stimulating glandular tissue. Nausea tends to be an oral-tablet effect, since the hormone is absorbed through the gut; taking the tablet with food or switching route are the sorts of adjustments a prescriber might consider. Bloating and fluid retention are more often linked to the progestogen component, as are premenstrual-style irritability or low mood in women who are sensitive to it.

Bleeding needs its own note. On cyclical regimens, where the progestogen is given for part of each month, a monthly withdrawal bleed is expected. On continuous combined regimens, spotting is common early on and often disappears by six months. Bleeding that starts after the pattern has settled, or any bleeding that is heavy or prolonged, is not a settling-in effect and warrants assessment, because it can signal a thickened endometrium.

Skin reactions belong to patches and gels specifically and are covered below. Headaches may improve or worsen; women with migraine with aura are usually steered toward transdermal routes because oral estrogen carries a higher stroke signal in that group.

The practical rule from guidance bodies is simple: give new therapy a reasonable settling period, keep notes on what bothers you, and bring that record to the review. Changing the hormone type, the progestogen or the route resolves most persistent early side effects, and that decision sits with the prescriber.

What are the long-term side effects of HRT?

Long-term risk is where the evidence is both strongest and most misquoted, so precision matters.

Breast cancer is the headline. In the WHI, combined estrogen-progestogen therapy produced about eight extra invasive breast cancers per 10,000 women per year compared with placebo, a risk that rose with duration and declined after stopping. Estrogen-only therapy in women with a hysterectomy showed no increase and, over long follow-up, somewhat fewer breast cancers. Observational data suggest regimens using micronized progesterone may carry a smaller breast signal than those using synthetic progestins, but that comparison has not been tested head-to-head in a large randomized trial.

Blood clots in the veins, called venous thromboembolism (VTE), roughly doubled with oral combined therapy in the WHI, from about 8 to 18 events per 10,000 woman-years. Stroke rose by about eight per 10,000 woman-years. Both risks concentrate in the first year or two and are higher in older starters.

Endometrial cancer increases with estrogen taken alone by a woman who still has a uterus; adequate progestogen brings the risk back to baseline, which is why combined therapy exists. Gallbladder disease is more common with oral estrogen, consistent with its effect on bile composition. A meta-analysis of observational studies found a small increase in ovarian cancer with longer use, on the order of one extra case per 1,000 users over five years; the certainty is moderate at best.

Dementia is the most nuanced entry. The WHI Memory Study found more probable dementia among women who started combined therapy at 65 or older. For women starting in their 50s, randomized data show neither harm nor protection on cognition. HRT is not used to prevent memory decline.

Breast cancer and HRT: what the numbers really show

Relative risks make headlines; absolute numbers make decisions. The WHI combined arm reported a hazard ratio of about 1.26 for invasive breast cancer, which sounds like a quarter more cancer. Translated into absolute terms for women in their 50s, it means roughly four to eight additional cases per 1,000 women over five years of use, on top of a background rate that is itself modest at that age. The NHS frames it similarly: a small increase, larger with longer use, and smaller than the increase associated with carrying excess weight after menopause or drinking alcohol regularly.

Three features of the data deserve emphasis. The risk is tied to the progestogen-containing regimen; the estrogen-only arm went the other way. The risk falls after stopping and returns toward baseline within a few years. And the trials did not find more deaths from breast cancer in the 18-year follow-up, though they were not large enough to rule out a small effect.

Mechanistically, estrogen and progestogens can promote the growth of hormone-sensitive cells that are already present rather than creating new tumors, which fits the pattern of risk rising during use and falling afterward. Combined HRT also increases mammographic density, which can make screening images harder to read; this is worth mentioning at the time of a mammogram.

Screening recommendations do not change because a woman uses HRT. Routine mammography in the US generally begins at 40 and continues at intervals set by national guidance, with earlier or more frequent screening for those at higher inherited risk. A personal history of breast cancer is usually a reason not to use systemic HRT; a family history is a reason for a careful conversation rather than an automatic no. That conversation belongs with the treating clinician.

Blood clots, stroke and the heart: does the route of HRT matter?

Here is where the oral-versus-transdermal distinction stops being a technicality. Estrogen swallowed as a tablet reaches the liver in concentrated form before entering general circulation, and the liver responds by producing more clotting factors. Estrogen absorbed through the skin arrives in the bloodstream gradually and skips that first pass.

The randomized evidence for VTE comes almost entirely from oral products: the WHI doubling described above, with the highest risk in the first year. The reassurance about transdermal estrogen comes from large observational studies, including UK primary care databases, which have found little or no increase in clot risk with patches and gels at standard strengths. Observational data cannot prove safety the way a trial can, but the consistency of the finding and the plausible mechanism have persuaded most guideline bodies to prefer transdermal routes for women with clot risk factors.

Stroke shows a similar pattern. Oral therapy added about eight strokes per 10,000 woman-years in the WHI, and the risk tracked with age and blood pressure. Observational data again point to a smaller signal with transdermal delivery.

Coronary heart disease is the outcome that produced the famous reversal. The WHI combined arm showed about seven extra coronary events per 10,000 woman-years overall, concentrated in older starters. Reanalysis by age, supported by later trials of younger women, found neutral or slightly favorable heart outcomes in those starting under 60 or within 10 years of menopause. This “timing hypothesis” is biologically plausible but rests on subgroup and observational data, so it is graded moderate. The American Heart Association’s position remains that HRT should not be prescribed to prevent heart disease, and nothing in the 2025 label change alters that.

What are the potential side effects of HRT patches?

Patches carry the same systemic effects as any other estrogen route, plus a short list of their own.

Skin reactions top it. The adhesive, not the hormone, is the usual culprit, producing redness, itching or a faint rash at the site that fades within days of removal. Rotating application sites and avoiding freshly moisturized skin reduces this, and persistent reactions are a reason to discuss another brand or route rather than to push through.

Adhesion problems are the second category. Heat, humidity, sweat, oily skin and vigorous exercise all loosen patches, and a patch that lifts at the edges delivers less hormone, which can show up as a return of flashes before the next change is due. Swimming and bathing are generally fine with modern patches, but prolonged soaking in hot water can be the exception. Manufacturers’ leaflets specify timing and placement; the prescriber confirms what applies to the individual product.

Systemically, patch users report the same breast tenderness, bloating and early spotting as tablet users, though nausea is less common because the gut is bypassed. Headaches can occur. Because patches release hormone steadily rather than in a daily peak, some women notice fewer day-to-day fluctuations in mood or symptoms.

The long-term entries change in one important way. Observational data link transdermal estrogen to a lower clot and stroke signal than oral estrogen, which is why patches are often the first suggestion for women with higher body weight, migraine with aura, high blood pressure or a family history of VTE. The breast cancer and endometrial considerations do not change with route; they depend on the hormones used and the duration. Visible, mild residue on the skin after removal is harmless and washes off.

Switching from HRT patches to gel: what can change

Switching from a patch to a gel keeps the hormone and the route the same, so the long-term profile is essentially unchanged. The practical experience, though, can shift in several ways, and most of what follows comes from product labeling and clinical experience rather than trials.

Absorption becomes more variable. A patch delivers a fixed amount through a fixed area of skin; a gel depends on how much is applied, over what area, and whether the skin is clean, dry and unbroken. Early in a switch, some women notice symptoms returning or breast tenderness increasing while the two methods are matched. That matching is the prescriber’s job, and it may take more than one review.

Transfer is the side effect unique to gels. Alcohol-based estradiol gel sits on the surface until it dries and can pass to anyone who touches the area, including children, partners and pets. Labels advise washing hands after applying, letting the area dry fully before dressing, and avoiding skin-to-skin contact at the site for a period afterward. Reported cases of unintended exposure in children are rare but documented.

Skin irritation moves rather than disappears. The patch adhesive reaction goes away; a smaller number of women get dryness or stinging from the alcohol base, particularly on freshly shaved or sensitive skin. Sunscreen and moisturizer applied at the same time can affect absorption, which is why labels specify a gap.

Routine changes too. A daily step replaces a twice-weekly one, and missed applications produce symptom dips within a day or two. None of this makes gel better or worse; it makes it different. Women who sweat heavily, react to adhesives or want a more adjustable regimen often prefer gel, and the decision belongs with the clinician.

Stopping HRT patches abruptly: what happens and what the trials say

Stopping a patch is mechanically easy, which is partly why it happens unplanned: a prescription runs out, a travel bag is lost, a headline frightens. The hormone level falls over a few days, and the body responds much as it did at the original menopause.

Symptom recurrence is the main effect. In follow-up studies, roughly half of women experience a return of hot flashes and night sweats within weeks of stopping, sometimes briefly more intense than before treatment because the body has adjusted to a steady supply. Sleep disturbance, irritability and vaginal dryness commonly return as well, often over a longer period for the genitourinary symptoms since tissue changes lag hormone changes.

Whether tapering helps is a fair question with an honest answer: the evidence is thin. Small randomized trials that compared abrupt stopping with gradual reduction found similar rates of symptom return months later, though some women found the gradual path more comfortable. UK guidance leans toward gradual reduction because it allows symptoms to be monitored and the plan revised; US guidance says either approach is reasonable. In both, the sequence and timing are set by the prescriber, not improvised.

Bone is the quieter consequence. Protection against bone loss is not banked; bone turnover rises again after stopping, and women at fracture risk may need a different strategy, which is a conversation to have before stopping rather than after.

What abrupt stopping does not do matters too. There is no withdrawal syndrome in the sense of physical dependence, no danger from a sudden drop in itself, and no evidence that stopping suddenly causes lasting harm. The risks tied to therapy, clots and breast cancer among them, begin to decline after stopping regardless of method.

What the evidence actually says: grading the HRT claims

Evidence comes in tiers. Randomized controlled trials, where participants are assigned by chance to treatment or placebo, give the most trustworthy answers about cause and effect. Observational studies compare people who chose different paths and can be distorted by why they chose them. Expert opinion fills the gaps where neither exists.

High certainty, from randomized trials: systemic estrogen relieves hot flashes and night sweats; systemic HRT reduces fractures; local vaginal estrogen treats genitourinary symptoms; oral combined therapy increases VTE, stroke and breast cancer by the small absolute amounts described above; unopposed estrogen increases endometrial cancer; combined therapy started at 65 or older increases probable dementia; long-term all-cause mortality is not increased.

Moderate certainty, from large observational studies and trial subgroups: transdermal estrogen carries a lower clot and stroke risk than oral; starting under 60 or within 10 years of menopause gives a neutral-to-favorable heart profile; micronized progesterone may carry a smaller breast signal than synthetic progestins; longer use slightly increases ovarian cancer.

Low certainty, from small trials, patient reports or expert consensus: improvements in joint pain, skin, concentration and mood beyond what comes from better sleep; a smaller breast signal with some regimens; the benefit of tapering over stopping; most claims about testosterone added to HRT for symptoms other than low sexual desire.

Not tested at all: compounded “bioidentical” hormone mixtures, which are unapproved, unstandardized and not for self-use; pellet implants of hormone mixtures sold outside regulated channels; and almost everything promised about weight loss or anti-aging. Guidance from the NHS, Mayo Clinic and Cleveland Clinic draws the same lines, and the 2025 label change adjusted the warning language, not the grades.

HRT side effects versus benefits: the balance sheet at a glance

The table below uses the WHI combined estrogen-progestogen findings, expressed as the change in events per 10,000 women per year compared with placebo, because those are the only randomized numbers large enough to quote with confidence. Women in that trial averaged 63 at entry and used oral tablets; younger women on transdermal estrogen generally sit on the more favorable side of each row, as the evidence grade column notes.

Outcome	Direction with combined HRT	Approximate change per 10,000 women per year (WHI)	Evidence grade
Hot flashes and night sweats	Large improvement	About 75% fewer episodes	High (multiple randomized trials)
Hip fracture	Fewer	About 5 fewer	High (randomized)
Colorectal cancer	Fewer	About 6 fewer	Moderate (single trial finding)
Invasive breast cancer	More, duration-related	About 8 more	High (randomized); smaller with estrogen-only
Venous blood clot	More, oral route	Roughly doubled, about 8 to 18	High for oral; transdermal lower on observational data
Stroke	More, age-related	About 8 more	High (randomized)
Coronary heart disease	More in older starters; neutral or lower under 60	About 7 more overall	Moderate for age effect
Probable dementia (started at 65+)	More	About 23 more	High for older starters; unknown for younger
All-cause death at 18 years	No difference	No change	High (randomized follow-up)

Two readings of this table are both correct. Every harm is rare in absolute terms, which is why guidance supports HRT for symptomatic women in their 50s. Every harm is also real, which is why guidance also asks for an annual review, a reason to continue, and attention to route and age. The numbers do not settle the decision; they describe its shape.

Common myths about HRT side effects, corrected

Viral claims about HRT tend to be half-true, which is what makes them durable. A few that deserve correction:

• “HRT doubles your breast cancer risk.” The WHI found about a quarter increase in relative terms with combined oral therapy, equal to a handful of extra cases per 1,000 women over five years, and no increase with estrogen-only therapy. The risk falls after stopping.
• “The warning was removed, so HRT is now risk-free.” The 2025 change altered the boxed warning language; the detailed labeling still describes clot, stroke and cancer risks, and the trial data behind them did not change.
• “HRT makes you gain weight.” Randomized trials show no difference in weight between HRT and placebo groups. Midlife weight gain happens with or without treatment; early bloating is fluid, not fat, and usually passes.
• “You must stop after five years, or at 60.” No guideline sets a fixed stop date. Risks rise with duration, so each year the question is whether benefits still justify continuing, answered at review with the prescriber.
• “Natural or bioidentical compounded hormones are safer.” Regulated estradiol and micronized progesterone are already body-identical and have trial data. Compounded mixtures are unapproved, vary batch to batch and have no safety data; they are not for self-use.
• “HRT prevents heart disease” or “HRT causes heart disease.” Neither. Younger starters show a neutral-to-favorable heart profile; older starters show harm; no guideline recommends HRT to protect the heart.
• “HRT just postpones menopause.” Symptoms often return after stopping because the underlying hormone change remains, not because treatment delayed it. Menopause itself happened on schedule.

The thread running through these myths is the loss of absolute numbers. Reattach them and most of the fear and most of the hype dissolve together.

When to see a doctor about HRT side effects

Most HRT side effects are mild and temporary, and most questions can wait for a scheduled review. A short list cannot. Seek urgent medical care, by emergency services if needed, for any of the following while using HRT:

• Swelling, pain, warmth or redness in one calf or thigh, which can indicate a clot in a deep vein.
• Sudden chest pain, breathlessness or coughing up blood, which can indicate a clot that has traveled to the lung.
• Sudden weakness or numbness on one side, facial drooping, slurred speech, confusion or loss of vision, which can indicate a stroke.
• A severe headache unlike any you have had before, or a migraine with new visual aura.
• Yellowing of the skin or eyes, dark urine or severe upper abdominal pain, which can indicate liver or gallbladder problems.

Book a non-urgent appointment, rather than waiting for the annual review, if bleeding starts after the pattern has settled, becomes heavy or continues beyond the first six months of a continuous regimen; if you notice a new lump, skin change or nipple discharge in either breast; if blood pressure readings rise; if side effects have not eased after about three months; or if you are considering stopping, switching or restarting for any reason. Abrupt changes made alone are where most avoidable problems begin.

Routine care matters as much as red flags. Guidance bodies advise a review within the first few months of starting and at least yearly afterward, covering symptoms, blood pressure, bleeding, breast and cervical screening status, and whether the original reason for treatment still applies. HRT is also not usually recommended for women with a history of breast cancer, estrogen-sensitive cancer, unexplained vaginal bleeding, previous VTE or stroke, or active liver disease; a clinician can weigh exceptions and alternatives. Every decision about starting, changing or stopping belongs with the prescribing clinician, who holds the full history.

Frequently asked questions

What are the long-term side effects of HRT?

The long-term risks are small absolute increases in breast cancer with combined therapy, venous clots and stroke with oral estrogen, gallbladder disease with oral estrogen, and endometrial cancer if estrogen is taken without a progestogen by a woman with a uterus. Breast cancer risk rises with duration and falls after stopping. Dementia risk rose only in women starting at 65 or older. Long-term all-cause mortality was not increased in 18-year trial follow-up.

What are the potential side effects of HRT patches?

Patches can cause redness, itching or rash at the site from the adhesive, and may lift in heat or with sweating, which lowers hormone delivery and lets symptoms return. Systemically they share the breast tenderness, bloating and early spotting seen with other routes, though nausea is less common. Observational studies link transdermal estrogen to a lower clot and stroke signal than tablets; breast and endometrial considerations do not change with route.

What are the potential side effects of changing from HRT patches to gel?

Because both are transdermal estradiol, long-term risks do not change, but the experience can. Absorption is more variable with gel, so symptoms or breast tenderness may fluctuate while the prescriber matches the two methods. Gel can transfer to children, partners or pets until dry, and its alcohol base can sting sensitive skin. Missed daily applications cause symptom dips faster than with patches. The switch itself is managed by the clinician.

What are the potential side effects of abruptly stopping HRT patches?

Hot flashes, night sweats, sleep disturbance and vaginal dryness return in roughly half of women within weeks, sometimes briefly more intense than before treatment. Bone protection does not persist, so bone loss resumes. There is no withdrawal syndrome and no evidence that sudden stopping causes lasting harm; small trials found similar symptom recurrence with abrupt and gradual stopping. Any plan to stop should be agreed with the prescribing clinician.

What are the main HRT benefits beyond hot flashes?

The best-proven HRT benefits beyond hot flashes are fewer fractures, including hip fractures, and relief of vaginal dryness, pain with sex and urinary symptoms, which local vaginal estrogen treats on its own. Sleep and mood often improve as night sweats stop. Trial data also showed fewer colorectal cancers, though HRT is not prescribed for that. Claims about joint pain, skin and memory rest on weaker evidence.

Does HRT cause weight gain?

Randomized trials have not found a difference in weight between women taking HRT and women taking placebo. Weight gain around midlife is common whether or not someone uses hormone therapy and is driven by aging, muscle loss and activity changes. Early bloating on HRT is fluid retention, often linked to the progestogen, and usually passes within a few months rather than becoming lasting weight.

How long is it safe to stay on HRT?

No guideline sets a fixed maximum. Risks such as breast cancer rise gradually with duration, so guidance bodies recommend an annual review that asks whether the original reason for treatment still applies and whether benefits still outweigh risks. Many women use HRT for a few years around the transition; some continue longer with ongoing symptoms or fracture risk. The decision is made with the prescribing clinician.

Is HRT safe to start after 60?

Starting after 60, and especially after 65, moves several risks upward: stroke, clots and, in the WHI Memory Study, probable dementia. Women who started in their 50s and continue past 60 are in a different position from women starting fresh at that age. Local vaginal estrogen remains an option at any age for genitourinary symptoms. A clinician weighs individual history before advising on systemic therapy later in life.

Are compounded bioidentical hormones safer than regular HRT?

No evidence supports that claim. Regulated estradiol and micronized progesterone are already identical to the body’s own hormones and have trial data behind them. Compounded mixtures are custom-prepared, not approved by regulators, vary between batches and have no safety or effectiveness studies. Guidance from the NHS, Mayo Clinic and Cleveland Clinic advises against them, and they are not for self-use.

Does HRT raise breast cancer risk for every woman who takes it?

No. In randomized trials the increase appeared with combined estrogen-progestogen therapy, at about eight extra cases per 10,000 women per year, and rose with duration. Estrogen-only therapy in women who had a hysterectomy showed no increase and somewhat fewer cases over long follow-up. Local vaginal estrogen is not linked to breast cancer. Personal and family history change the picture, which is why the decision belongs with a clinician.

References

• NHS: Benefits and risks of hormone replacement therapy (HRT)
• NHS: Side effects of hormone replacement therapy (HRT)
• Cleveland Clinic: Hormone Therapy for Menopause Symptoms
• MedlinePlus: Hormone Replacement Therapy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.